Radioactive injection shows promise against Hard-to-Treat gut cancers
NCT ID NCT05884255
First seen May 10, 2026 · Last updated May 23, 2026 · Updated 3 times
Summary
This study tests a new treatment for advanced neuroendocrine tumors of the gut and pancreas that cannot be removed by surgery. About 220 adults will receive either a radioactive drug (lutetium-177) plus standard-dose long-acting octreotide, or high-dose octreotide alone. The goal is to see which approach better delays tumor growth and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED GASTROENTEROPANCREATIC NEUROENDOCRINE TUMOR are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 201321, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Tianjin University Cancer Institute and Hospital
RECRUITINGTianjin, Tianjin Municipality, 300060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.